Floatz logo

Epoetin Alfa

Friedreich Ataxia

Federico II UniversityPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Friedreich Ataxia cohort.

Asset / SponsorPhaseRating
Idebenone
Santhera Pharmaceuticals
Phase 3A
Interferon Γ-1B
Amgen
Phase 3BB
Omaveloxolone
Biogen
Phase 3BB
rt001
Biojiva LLC
Phase 3BB
Trans-Resveratrol
Murdoch Childrens Research Institute
Phase 2BB

View all 38 →

Same molecule, other indications

Epoetin Alfa is also rated in:

anemiaDormant
BBB
Indicative ·
79 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
71 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →